A single-dose study of HP-6050

JRCT ID: jRCT2031220092

Registered date:25/05/2022

Basic Information

• Recruitment status: Complete
• Health condition(s) or Problem(s) studied: Healthy adult
• Date of first enrollment: 31/05/2022
• Target sample size: 16
• Study type: Interventional
• Intervention(s): Single dose of HP-6050

Outcome(s)

• Primary Outcome: Pharmacokinetic parameters, adverse events
• Secondary Outcome: Pharmacodynamics

Key inclusion & exclusion criteria

• Age minimum: >= 18age old
• Age maximum: < 40age old
• Gender: Both

Include criteria

- Healthy Japanese adult males and females aged >=18 and <40 years
- Body mass index (BMI) is >=18.5 and <25.0

Exclude criteria

- Subjects with vagal tone
- Subjects with current or history of serious cardiac, vascular, renal, hepatic, psychiatric/neurological, or metabolic diseases
- Subjects who received any drug within a week prior to application of the study drug

Related Information

• Primary Sponsor: Inakura Hiroshi